{
    "clinical_study": {
        "@rank": "85740", 
        "acronym": "ICICLE", 
        "arm_group": [
            {
                "arm_group_label": "Q/LAIV", 
                "description": "FluMist Quadrivalent"
            }, 
            {
                "arm_group_label": "Inactivated Influenza Vaccine", 
                "description": "Inactivated Influenza Vaccine"
            }
        ], 
        "biospec_descr": {
            "textblock": "A nasal swab specimen will be collected and tested for influenza and other viral pathogens."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is a post-marketing case-controlled study of the effectiveness of a quadrivalent live\n      attenuated influenza vaccine (Q/LAIV/FluMist\u00ae Quadrivalent) versus Inactivated Influenza\n      Vaccine (IIV) and No Vaccine in subjects 2-17 years of age."
        }, 
        "brief_title": "A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza Vaccine Effectiveness", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "This post-marketing study will enroll approximately 5,200 subjects 2-17 years of age who are\n      seeking care in an outpatient setting for febrile acute respiratory illness.  This study\n      will begin in the fall of 2013 and will be completed after 4 influenza seasons (i.e.after\n      the 2016-2017 influenza season).  No investigational product will be administered in this\n      study.  A nasal swab will be obtained and tested for the presence of influenza virus and\n      other viral pathogens. This study will be conducted at 4 sites in the United States of\n      America.  The duration of study participation for each subject is one day."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Community-dwelling children and adolescents 2 to 17 years of age.\n\n          -  Written Informed Consent or Assent.\n\n          -  Acute respiratory illness documented at study visit or at home with fever (oral\n             temperature \u2265 100.0\u00b0 Fahrenheit at study visit, or history of fever reported by\n             parents, or use of antipyretic prior to study visit)\n\n          -  Symptom onset less than 5 days prior to study visit.\n\n          -  Subject and/or subject's legal representative is able to understand and comply with\n             the requirements of the protocol as judged by the investigator.\n\n        Exclusion Criteria:\n\n          -  Treatment with an antiviral drug for influenza (oseltamivir or Tamiflu\u00ae, zanamivir or\n             Relenza\u00ae) during the 14 days before enrollment\n\n          -  Any condition that, in the opinion of the investigator, would interfere with\n             interpretation of subject safety or study results\n\n          -  Concurrent enrollment in another clinical study\n\n        Patient already enrolled during this influenza season\n\n          -  Employees of the clinical study site or any other individuals involved with the\n             conduct of the study, or immediate family members of such individuals."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects 2 to 17 years of age who are seeking care in an outpatient setting for febrile\n        acute respiratory illness."
            }
        }, 
        "enrollment": {
            "#text": "5200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01997450", 
            "org_study_id": "MA-VA-MEDI3250-1116"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Q/LAIV/FluMist\u00ae Quadrivalent Vaccine, Inactivated Influenza Vaccine (IIV), Effectiveness, Influenza", 
        "lastchanged_date": "January 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27157"
                    }, 
                    "name": "Wake Forrest School of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37212"
                    }, 
                    "name": "Vanderbilt University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Temple", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76508"
                    }, 
                    "name": "Scott and White Memorial Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marshfield", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "54449"
                    }, 
                    "name": "Marshfield Clinical Research Foundation"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Naomi Veney", 
            "phone": "301-398-0000"
        }, 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "Herve Caspard, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vaccine Effectiveness is defined as 100 x (1-odds ratio), where the odds ratio is the odds of exposures (Q/LAIV versus Inactivated Influenza Vaccine or no vaccine) among laboratory confirmed cases of flu versus controls. Effectiveness will be monitored by flu season, class of age and by influenza strain.", 
            "measure": "Identification of cases positive for wild-type influenza with an end-point PCR genotyping assay.", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 months for each individual flu season"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01997450"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "MedImmune LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}